SLN // Silence Therapeutics Plc American Depository Share
FA <GO> NASDAQ RQD COCKPIT → CIK 0001479615 ↗ Health Care • Biotechnology: Pharmaceutical Preparations
$19.80 ▲ +0.09
(+0.46%)
MKT CAP: $1.23B • VOL: 1.81M
52W L $4 52W H $20
SLN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $559.0K | $43.3M | $31.6M |
| YoY Revenue Growth % | -98.7% | +36.7% | — |
| Gross Profit | $344.0K | $31.4M | — |
| Gross Margin % | 61.5% | 72.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$91.1M | -$63.3M | -$64.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$88.6M | -$45.3M | -$54.2M |
| EBITDA (Normalized) | -$91.0M | -$63.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$62.3M | -$67.6M | -$49.5M |
| Capital Expenditures (CapEx) | $55.0K | $211.0K | — |
| Free Cash Flow (FCF) | -$62.3M | -$67.9M | -$49.5M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $11.3M | $121.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $62.3M | $134.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SLN.